I move:
That, pursuant to Standing Order 233(2), Standing Order 187 is modified to provide that it be an instruction to the Committee on the Health Insurance (Amendment) Bill 2024, that it has the power to make amendments to the Bill which are outside the scope of the existing subject matter of the Bill, in relation to:
the Health Act 1970, to provide that HSE Guidelines on "ordinarily resident in the State" apply to certain women who receive menopause products;
the Health Act 1970, to provide for the making available for supply to women, without charge, of certain products used to alleviate the symptoms of menopause and for the provision of a regulation-making power for the Minister for Health in this regard; and
the Health (Pricing and Supply of Medical Goods) Act 2013, to provide for the HSE's conditional supply and reimbursement of listed menopause products, meaning hormone replacement therapy drugs, medicines and surgical and medical appliances, used to alleviate the symptoms of menopause and which are on the Reimbursement List as administered by the HSE;
and to make other consequential amendments required to take account of the changes above.
The purpose of this motion is to instruct the Dáil, in committee, that Standing Order 187 is modified in accordance with Standing Order 233(2) to provide that the committee has the power to make amendments to the Health Insurance (Amendment) Bill 2024 that are outside the existing subject matter of the Bill.
I am pleased to say that Government approval was recently received to bring amendments to the Health Insurance (Amendment) Bill 2024 to provide the legal basis for the introduction of free HRT, or State-funded hormone replacement therapy, and the moving of these amendments on Committee Stage. The proposed amendments will provide a legal basis for the provision of HRT to women experiencing the symptoms of menopause. This will mean that where a woman has been prescribed HRT by her healthcare provider to alleviate the symptoms associated with all stages of menopause, the cost of these medications and products will be met by the State.
A new section 67F is proposed to be included in the Health Act 1970 to provide for free menopause medicines and products to women who have been prescribed menopause medicines by their healthcare provider to alleviate the symptoms of menopause. Section 47A of the Health Act 1970 will be also amended to provide that existing guidelines on “ordinarily resident in the State” will apply to the women who receive free menopause products under this measure.
Section 20 of the Health (Pricing and Supply of Medical Goods) Act 2013 is to be amended to provide for the HSE’s continual supply or reimbursement of menopause products on the HSE reimbursement list, while section 23 of the Act is to be amended to provide for the HSE’s discretion for the supply of menopause products that are not on the reimbursement list.
Since I became Minister for Health in 2020, progressing and helping to bring about a revolution in women’s healthcare has been a top priority for me and this Government. The Government made a strong commitment to promoting women’s health in the programme for Government. I am proud to say that since then, the Government has allocated approximately €180 million to be targeted at new developments in women’s healthcare. We have heard from many women that they often feel dismissed in their experience with menopause, that the cost of menopause care is a burden, and that some women have even considered giving up their jobs due to the severity of their symptoms. This legislation, when enacted, will mean that where a woman has been prescribed HRT by her healthcare provider to alleviate the symptoms associated with all stages of menopause, the cost of those medications and products will be met by the State. This will relieve some of the cost burden we have heard about.
In line with established policy, HRT medications and products covered will be those that are included on the HSE reimbursement list. In order to progress this work to lower the cost of menopause, I have allocated €20 million to implement this new measure in 2025. The measure does not cover the cost of consultations with healthcare providers, costs for pharmacists, or costs for the insertion or removal of a coil. These matters can and should be considered as matters of policy in future expansion of the scheme.
We have made important progress in menopause care in recent years. This includes the establishment of specialist clinics for the treatment of complex menopause cases. We have increased awareness among our clinicians through the development of training and a quick reference guide for GPs and practice nurses to upskill in identifying and treating symptoms of menopause. In budget 2023, we began the process of relieving the short-term costs of menopause on women with the removal of VAT from HRT products. This new measure today represents the next step in this process.
Hormone replacement therapy is the most commonly used treatment for managing menopausal symptoms and has been shown to be the most effective intervention for management of these symptoms. Many women will spend a good portion of their lifetime going through the various stages of menopause. This measure aims to make this transitional period a little easier by making HRT more accessible to everybody who needs it and providing it for free, or State-funded.
I ask for the support of Members of the House for the motion to enable these important amendments to be tabled.